Texas Retina Recognizes Laurie Griffis for 35 Years of Service
Since Texas Retina was founded more than 50 years ago, our physicians and leadership have fostered a family environment. As a result, we are fortunate to have numerous team members who have
read more
New Clinical Trials Available at Texas Retina
At Texas Retina Associates, we remain committed to conducting ongoing research that will improve care for our patients, and over the past 20 years, our research program has grown to become one
read more
Celebrating Our Visionary Founders
Many of our “founding physicians” met for dinner this past weekend, including Albert Vaiser, MD, and William Hutton, MD, who along with William Snyder, MD, established Texas Retina Associates more than 50 years
read more
Dr. Abbey Publishes Case Report on Macular Hole Closure with Intravitreal Dexamethasone Implant
In the September 2023 issue of the peer-reviewed medical journal Ophthalmic Surgery, Lasers and Imaging Retina, Texas Retina’s Ashkan Abbey, MD, describes the use of a dexamethasone intravitreal implant to close a
read more
New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more Dr. Abbey Publishes Research on Effectiveness of a Long-acting Injectable Steroid for Patients with Cystoid Macular Edema After Vitrectomy
Long-acting injectable steroids have emerged as a new way to treat chronic intraocular inflammation and cystoid macular edema (CME) that reduces the treatment frequency and burden for retina patients. Texas Retina’s Ashkan
read more Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more New Clinical Trials Available
At Texas Retina Associates, our physicians remain actively involved in conducting research that will improve care for our patients, offering access to promising new retinal treatments through clinical trials. We recently opened
read more Dr. Abbey Featured in Retina Times
Texas Retina Associates’ Ashkan Abbey, MD, was featured in the “5 Questions” segment of the latest issue of Retina Today. In the article, he discusses his passion for retina research, what led
read more